Temozolomide nanoparticles for targeted glioblastoma therapy

ACS Applied Materials and Interfaces

Volumn 7, Issue 12, 2015, Pages 6674-6682

  Fang, Chen ^a,b   Wang, Kui ^b   Stephen, Zachary R ^b   Mu, Qingxin ^a,b   Kievit, Forrest M ^c   Chiu, Daniel T ^d   Press, Oliver W ^a,b,d   Zhang, Miqin ^b,c  

^a Fred Hutchinson Cancer Research Center   (United States)

^b University of Washington   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF WASHINGTON   (United States)

Author keywords

chlorotoxin; drug delivery; glioblastoma; MGMT; nanomedicine; therapeutics

Indexed keywords

CELL CULTURE; CELLS; CHEMOTHERAPY; CONTROLLED DRUG DELIVERY; DIAGNOSIS; DRUG DELIVERY; MEDICAL NANOTECHNOLOGY; NANOPARTICLES; PH; PHYSIOLOGY; SYNTHESIS (CHEMICAL); TUMORS;

CELL CULTURE MEDIA; CHLOROTOXIN; GLIOBLASTOMAS; MGMT; PHYSIOLOGICAL SOLUTION; SYSTEMIC TOXICITIES; THERAPEUTICS; TUMOR TARGETING PEPTIDES;

TARGETED DRUG DELIVERY;

ANTINEOPLASTIC AGENT; DACARBAZINE; DRUG CARRIER; NANOPARTICLE; TEMOZOLOMIDE;

ANALOGS AND DERIVATIVES; ANIMAL; BRAIN NEOPLASMS; C57BL MOUSE; CHEMISTRY; DEVICES; DRUG DELIVERY SYSTEM; EVALUATION STUDY; GLIOBLASTOMA; HUMAN; MOUSE; PROCEDURES; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; DACARBAZINE; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; GLIOBLASTOMA; HUMANS; MICE; MICE, INBRED C57BL; NANOPARTICLES;

EID: 84926303592     PISSN: 19448244     EISSN: 19448252     Source Type: Journal    
DOI: 10.1021/am5092165     Document Type: Article

References (43)

1. Ostrom, Q. T.; Gittleman, H.; Liao, P.; Rouse, C.; Chen, Y.; Dowling, J.; Wolinsky, Y.; Kruchko, C.; Barnholtz-Sloan, J. Cbtrus Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011 Neuro-Oncology (Cary, NC, U.S.) 2014, 16 (Suppl. 4) iv, 1-63
2. Wen, P. Y.; Kesari, S. Malignant Gliomas in Adults N. Engl. J. Med. 2008, 359, 492-507
3. Huse, J. T.; Holland, E.; DeAngelis, L. M. Glioblastoma: Molecular Analysis and Clinical Implications Annu. Rev. Med. 2013, 64, 59-70
4. Omuro, A. Glioblastoma and Other Malignant Gliomas JAMA, J. Am. Med. Assoc. 2013, 310, 1842
5. Parsons, D. W.; Jones, S.; Zhang, X.; Lin, J. C. H.; Leary, R. J.; Angenendt, P.; Mankoo, P.; Carter, H.; Siu, I.-M.; Gallia, G. L.; Olivi, A.; McLendon, R.; Rasheed, B. A.; Keir, S.; Nikolskaya, T.; Nikolsky, Y.; Busam, D. A.; Tekleab, H.; Diaz, L. A.; Hartigan, J.; Smith, D. R.; Strausberg, R. L.; Marie, S. K. N.; Shinjo, S. M. O.; Yan, H.; Riggins, G. J.; Bigner, D. D.; Karchin, R.; Papadopoulos, N.; Parmigiani, G.; Vogelstein, B.; Velculescu, V. E.; Kinzler, K. W. An Integrated Genomic Analysis of Human Glioblastoma Multiforme Science 2008, 321, 1807-1812
6. Chamberlain, M. C. Bevacizumab for the Treatment of Recurrent Glioblastoma Clin. Med. Insights: Oncol. 2011, 5, 117-129
7. Gilbert, M. R.; Dignam, J. J.; Armstrong, T. S.; Wefel, J. S.; Blumenthal, D. T.; Vogelbaum, M. A.; Colman, H.; Chakravarti, A.; Pugh, S.; Won, M.; Jeraj, R.; Brown, P. D.; Jaeckle, K. A.; Schiff, D.; Stieber, V. W.; Brachman, D. G.; Werner-Wasik, M.; Tremont-Lukats, I. W.; Sulman, E. P.; Aldape, K. D.; Curran, W. J., Jr.; Mehta, M. P. A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma N. Engl. J. Med. 2014, 370, 699-708
8. Zhang, J.; Stevens, M. F.; Bradshaw, T. D. Temozolomide: Mechanisms of Action, Repair and Resistance Curr. Mol. Pharmacol. 2012, 5, 102-114
9. Quinn, J. A.; Jiang, S. X.; Reardon, D. A.; Desjardins, A.; Vredenburgh, J. J.; Rich, J. N.; Gururangan, S.; Friedman, A. H.; Bigner, D. D.; Sampson, J. H.; McLendon, R. E.; Herndon, J. E., II; Walker, A.; Friedman, H. S. Phase II Trial of Temozolomide Plus O6-Benzylguanine in Adults with Recurrent, Temozolomide-Resistant Malignant Glioma J. Clin. Oncol. 2009, 27, 1262-1267
10. Patil, R.; Portilla-Arias, J.; Ding, H.; Inoue, S.; Konda, B.; Hu, J.; Wawrowsky, K. A.; Shin, P. K.; Black, K. L.; Holler, E.; Ljubimova, J. Y. Temozolomide Delivery to Tumor Cells by a Multifunctional Nano Vehicle Based on Poly(B- l -Malic Acid) Pharm. Res. 2010, 27, 2317-2329
11. Braun, K.; Wiessler, M.; Ehemann, V.; Pipkorn, R.; Spring, H.; Debus, J.; Didinger, B.; Koch, M.; Muller, G.; Waldeck, W. Treatment of Glioblastoma Multiforme Cells with Temozolomide-Bioshuttle Ligated by the Inverse Diels-Alder Ligation Chemistry Drug Des., Dev. Ther. 2009, 2, 289-301
12. Veiseh, O.; Sun, C.; Fang, C.; Bhattarai, N.; Gunn, J.; Kievit, F.; Du, K.; Pullar, B.; Lee, D.; Ellenbogen, R. G.; Olson, J.; Zhang, M. Specific Targeting of Brain Tumors with an Optical/Magnetic Resonance Imaging Nanoprobe across the Blood-Brain Barrier Cancer Res. 2009, 69, 6200-6207
13. Kievit, F. M.; Veiseh, O.; Fang, C.; Bhattarai, N.; Lee, D.; Ellenbogen, R. G.; Zhang, M. Chlorotoxin Labeled Magnetic Nanovectors for Targeted Gene Delivery to Glioma ACS Nano 2010, 4, 4587-4594
14. Graf, N.; Mokhtari, T. E.; Papayannopoulos, I. A.; Lippard, S. J. Platinum(IV)-Chlorotoxin (Ctx) Conjugates for Targeting Cancer Cells J. Inorg. Biochem. 2012, 110, 58-63
15. Huang, R.; Ke, W.; Han, L.; Li, J.; Liu, S.; Jiang, C. Targeted Delivery of Chlorotoxin-Modified DNA-Loaded Nanoparticles to Glioma via Intravenous Administration Biomaterials 2011, 32, 2399-2406
16. Sun, C.; Fang, C.; Stephen, Z.; Veiseh, O.; Hansen, S.; Lee, D.; Ellenbogen, R. G.; Olson, J.; Zhang, M. Tumor-Targeted Drug Delivery and MRI Contrast Enhancement by Chlorotoxin-Conjugated Iron Oxide Nanoparticles Nanomedicine 2008, 3, 495-505
17. Sun, C.; Veiseh, O.; Gunn, J.; Fang, C.; Hansen, S.; Lee, D.; Sze, R.; Ellenbogen, R. G.; Olson, J.; Zhang, M. In Vivo MRI Detection of Gliomas by Chlorotoxin-Conjugated Superparamagnetic Nanoprobes Small 2008, 4, 372-379
18. Veiseh, M.; Gabikian, P.; Bahrami, S.-B.; Veiseh, O.; Zhang, M.; Hackman, R. C.; Ravanpay, A. C.; Stroud, M. R.; Kusuma, Y.; Hansen, S. J.; Kwok, D.; Munoz, N. M.; Sze, R. W.; Grady, W. M.; Greenberg, N. M.; Ellenbogen, R. G.; Olson, J. M. Tumor Paint: A Chlorotoxin:Cy5.5 Bioconjugate for Intraoperative Visualization of Cancer Foci Cancer Res. 2007, 67, 6882-6888
19. Veiseh, O.; Gunn, J. W.; Kievit, F. M.; Sun, C.; Fang, C.; Lee, J. S. H.; Zhang, M. Inhibition of Tumor-Cell Invasion with Chlorotoxin-Bound Superparamagnetic Nanoparticles Small 2008, 5, 256-264
20. Veiseh, O.; Sun, C.; Gunn, J.; Kohler, N.; Gabikian, P.; Lee, D.; Bhattarai, N.; Ellenbogen, R.; Sze, R.; Hallahan, A.; Olson, J.; Zhang, M. Optical and MRI Multifunctional Nanoprobe for Targeting Gliomas Nano Lett. 2005, 5, 1003-1008
21. Mortensen, J. H.; Jeppesen, M.; Pilgaard, L.; Agger, R.; Duroux, M.; Zachar, V.; Moos, T. Targeted Antiepidermal Growth Factor Receptor (Cetuximab) Immunoliposomes Enhance Cellular Uptake in Vitro and Exhibit Increased Accumulation in an Intracranial Model of Glioblastoma Multiforme J. Drug Delivery 2013, 2013, 209205
22. Yoon, D. J.; Kwan, B. H.; Chao, F. C.; Nicolaides, T. P.; Phillips, J. J.; Lam, G. Y.; Mason, A. B.; Weiss, W. A.; Kamei, D. T. Intratumoral Therapy of Glioblastoma Multiforme Using Genetically Engineered Transferrin for Drug Delivery Cancer Res. 2010, 70, 4520-4527
23. Bhattarai, N.; Matsen, F. A.; Zhang, M. PEG-Grafted Chitosan as an Injectable Thermoreversible Hydrogel Macromol. Biosci. 2005, 5, 107-111
24. Arrowsmith, J.; Jennings, S. A.; Clark, A. S.; Stevens, M. F. G. Antitumor Imidazotetrazines. 41. Conjugation of the Antitumor Agents Mitozolomide and Temozolomide to Peptides and Lexitropsins Bearing DNA Major and Minor Groove-Binding Structural Motifs J. Med. Chem. 2002, 45, 5458-5470
25. Deshane, J.; Garner, C. C.; Sontheimer, H. Chlorotoxin Inhibits Glioma Cell Invasion Via Matrix Metalloproteinase-2 J. Biol. Chem. 2003, 278, 4135-4144
26. Bobola, M. S.; Kolstoe, D. D.; Blank, A.; Silber, J. R. Minimally Cytotoxic Doses of Temozolomide Produce Radiosensitization in Human Glioblastoma Cells Regardless of Mgmt Expression Mol. Cancer Ther. 2010, 9, 1208-1218
27. Carlson, B. L.; Grogan, P. T.; Mladek, A. C.; Schroeder, M. A.; Kitange, G. J.; Decker, P. A.; Giannini, C.; Wu, W.; Ballman, K. A.; James, C. D.; Sarkaria, J. N. Radiosensitizing Effects of Temozolomide Observed in Vivo Only in a Subset of O6-Methylguanine-DNA Methyltransferase Methylated Glioblastoma Multiforme Xenografts Int. J. Radiat. Oncol., Biol., Phys. 2009, 75, 212-219
28. Marttila, A. T.; Laitinen, O. H.; Airenne, K. J.; Kulik, T.; Bayer, E. A.; Wilchek, M.; Kulomaa, M. S. Recombinant Neutralite Avidin: A Non-Glycosylated, Acidic Mutant of Chicken Avidin That Exhibits High Affinity for Biotin and Low Non-Specific Binding Properties FEBS Lett. 2000, 467, 31-36
29. Tseng, C. L.; Wu, S. Y.; Wang, W. H.; Peng, C. L.; Lin, F. H.; Lin, C. C.; Young, T. H.; Shieh, M. J. Targeting Efficiency and Biodistribution of Biotinylated-Egf-Conjugated Gelatin Nanoparticles Administered via Aerosol Delivery in Nude Mice with Lung Cancer Biomaterials 2008, 29, 3014-3022
30. Hama, Y.; Urano, Y.; Koyama, Y.; Choyke, P. L.; Kobayashi, H. Activatable Fluorescent Molecular Imaging of Peritoneal Metastases Following Pretargeting with a Biotinylated Monoclonal Antibody Cancer Res. 2007, 67, 3809-3817
31. Nordlund, H. R.; Hytonen, V. P.; Laitinen, O. H.; Uotila, S. T.; Niskanen, E. A.; Savolainen, J.; Porkka, E.; Kulomaa, M. S. Introduction of Histidine Residues into Avidin Subunit Interfaces Allows pH-Dependent Regulation of Quaternary Structure and Biotin Binding FEBS Lett. 2003, 555, 449-454
32. Davis, M. E.; Zuckerman, J. E.; Choi, C. H. J.; Seligson, D.; Tolcher, A.; Alabi, C. A.; Yen, Y.; Heidel, J. D.; Ribas, A. Evidence of RNAi in Humans from Systemically Administered Sirna via Targeted Nanoparticles Nature 2010, 464, 1067-1070
33. Farokhzad, O. C.; Jon, S.; Khademhosseini, A.; Tran, T. N.; Lavan, D. A.; Langer, R. Nanoparticle-Aptamer Bioconjugates: A New Approach for Targeting Prostate Cancer Cells Cancer Res. 2004, 64, 7668-7672
34. Petros, R. A.; Desimone, J. M. Strategies in the Design of Nanoparticles for Therapeutic Applications Nat. Rev. Drug Discovery 2010, 9, 615-627
35. Fang, C.; Veiseh, O.; Kievit, F.; Bhattarai, N.; Wang, F.; Stephen, Z.; Li, C.; Lee, D.; Ellenbogen, R. G.; Zhang, M. Functionalization of Iron Oxide Magnetic Nanoparticles with Targeting Ligands: Their Physicochemical Properties and in Vivo Behavior Nanomedicine 2010, 5, 1357-1369
36. Ponten, J.; Macintyre, E. H. Long Term Culture of Normal and Neoplastic Human Glia Acta Pathol. Microbiol. Scand. 1968, 74, 465-486
37. Pattabiraman, D. R.; Weinberg, R. A. Tackling the Cancer Stem Cells: What Challenges Do They Pose? Nat. Rev. Drug Discovery 2014, 13, 497-512
38. Hegi, M. E.; Liu, L.; Herman, J. G.; Stupp, R.; Wick, W.; Weller, M.; Mehta, M. P.; Gilbert, M. R. Correlation of O6-Methylguanine Methyltransferase (MGMT) Promoter Methylation with Clinical Outcomes in Glioblastoma and Clinical Strategies to Modulate MGMT Activity J. Clin. Oncol. 2008, 26, 4189-4199
39. Stephen, Z. R.; Kievit, F. M.; Veiseh, O.; Chiarelli, P. A.; Fang, C.; Wang, K.; Hatzinger, S. J.; Ellenbogen, R. G.; Silber, J. R.; Zhang, M. Redox-Responsive Magnetic Nanoparticle for Targeted Convection-Enhanced Delivery of O6-Benzylguanine to Brain Tumors ACS Nano 2014, 8, 10383-10395
40. Gilbert, M. R.; Wang, M.; Aldape, K. D.; Stupp, R.; Hegi, M. E.; Jaeckle, K. A.; Armstrong, T. S.; Wefel, J. S.; Won, M.; Blumenthal, D. T.; Mahajan, A.; Schultz, C. J.; Erridge, S.; Baumert, B.; Hopkins, K. I.; Tzuk-Shina, T.; Brown, P. D.; Chakravarti, A.; Curran, W. J., Jr.; Mehta, M. P. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial J. Clin. Oncol. 2013, 31, 4085-4091
41. Spence, A. M.; Kiem, H. P.; Partap, S.; Schuetze, S.; Silber, J. R.; Peterson, R. A. Complications of a Temozolomide Overdose: A Case Report J. Neurooncol. 2006, 80, 57-61
42. Mrugala, M. M.; Chamberlain, M. C. Mechanisms of Disease: Temozolomide and Glioblastoma-Look to the Future Nat. Clin. Pract. Oncol. 2008, 5, 476-486
43. Agyare, E. K.; Curran, G. L.; Ramakrishnan, M.; Yu, C. C.; Poduslo, J. F.; Kandimalla, K. K. Development of a Smart Nano-Vehicle to Target Cerebrovascular Amyloid Deposits and Brain Parenchymal Plaques Observed in Alzheimer's Disease and Cerebral Amyloid Angiopathy Pharm. Res. 2008, 25, 2674-2684